CytomX Therapeutics
CTMX
CTMX
67 hedge funds and large institutions have $58.7M invested in CytomX Therapeutics in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 20 increasing their positions, 20 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
11% less funds holding
Funds holding: 75 → 67 (-8)
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Holders
67
Holding in Top 10
–
Calls
$81K
Puts
$18K
Top Buyers
| 1 | +$872K | |
| 2 | +$592K | |
| 3 | +$468K | |
| 4 |
Squarepoint
New York
|
+$233K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$107K |
Top Sellers
| 1 | -$642K | |
| 2 | -$566K | |
| 3 | -$536K | |
| 4 |
Two Sigma Advisers
New York
|
-$493K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$464K |